Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East

Nasreen Al Sayed, Khalid Al Waili, Fatheya Alawadi, Saeed Al-Ghamdi, Wael Al Mahmeed, Fahad Al-Nouri, Mona Al Rukhaimi, Khalid Al-Rasadi, Zuhier Awan, Mohamed Farghaly, Mohamed Hassanein, Hani Sabbour, Mohammad Zubaid, Philip Barter

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease (ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-specific guidelines for managing plasma lipids exist and there is a lack of use of guidelines developed in other regions. Methods A multidisciplinary panel of regional experts was convened to develop consensus clinical recommendations for the management of plasma lipids in the Middle East. The panel considered existing international guidelines and regional clinical experience to develop recommendations. Results The panel's recommendations include plasma lipid screening, ASCVD risk calculation and treatment considerations. The panel recommend that plasma lipid levels should be measured in all at-risk patients and at regular intervals in all adults from the age of 20 years. A scoring system should be used to calculate ASCVD risk that includes known lipid and non-lipid risk factors. Primary treatment targets include low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Lifestyle modifications should be first-line treatment for all patients; the first-line pharmacological treatment targeting plasma lipids in patients at moderate-to-high risk of ASCVD is statin therapy, with a number of adjunctive or second-line agents available. Guidance is also provided on the management of underlying conditions and special populations; of particular pertinence in the region are familial hypercholesterolaemia, diabetes and metabolic dyslipidaemia. Conclusions These consensus clinical recommendations provide practicing clinicians with comprehensive, region-specific guidance to improve the detection and management of plasma lipid disorders in patients in the Middle East.

Original languageEnglish
Pages (from-to)268-283
Number of pages16
JournalInternational Journal of Cardiology
Volume225
DOIs
Publication statusPublished - Dec 15 2016

Fingerprint

Middle East
Consensus
Lipids
Cardiovascular Diseases
Guidelines
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Dyslipidemias
LDL Cholesterol
Life Style
Pharmacology

Keywords

  • Cardiovascular disease
  • Dyslipidaemia
  • Guidelines
  • Lipid disorder
  • Middle East

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. / Al Sayed, Nasreen; Al Waili, Khalid; Alawadi, Fatheya; Al-Ghamdi, Saeed; Al Mahmeed, Wael; Al-Nouri, Fahad; Al Rukhaimi, Mona; Al-Rasadi, Khalid; Awan, Zuhier; Farghaly, Mohamed; Hassanein, Mohamed; Sabbour, Hani; Zubaid, Mohammad; Barter, Philip.

In: International Journal of Cardiology, Vol. 225, 15.12.2016, p. 268-283.

Research output: Contribution to journalReview article

Al Sayed, N, Al Waili, K, Alawadi, F, Al-Ghamdi, S, Al Mahmeed, W, Al-Nouri, F, Al Rukhaimi, M, Al-Rasadi, K, Awan, Z, Farghaly, M, Hassanein, M, Sabbour, H, Zubaid, M & Barter, P 2016, 'Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East', International Journal of Cardiology, vol. 225, pp. 268-283. https://doi.org/10.1016/j.ijcard.2016.09.081
Al Sayed, Nasreen ; Al Waili, Khalid ; Alawadi, Fatheya ; Al-Ghamdi, Saeed ; Al Mahmeed, Wael ; Al-Nouri, Fahad ; Al Rukhaimi, Mona ; Al-Rasadi, Khalid ; Awan, Zuhier ; Farghaly, Mohamed ; Hassanein, Mohamed ; Sabbour, Hani ; Zubaid, Mohammad ; Barter, Philip. / Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. In: International Journal of Cardiology. 2016 ; Vol. 225. pp. 268-283.
@article{1b6d4daca1384fb18c75faa6a5438327,
title = "Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East",
abstract = "Background Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease (ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-specific guidelines for managing plasma lipids exist and there is a lack of use of guidelines developed in other regions. Methods A multidisciplinary panel of regional experts was convened to develop consensus clinical recommendations for the management of plasma lipids in the Middle East. The panel considered existing international guidelines and regional clinical experience to develop recommendations. Results The panel's recommendations include plasma lipid screening, ASCVD risk calculation and treatment considerations. The panel recommend that plasma lipid levels should be measured in all at-risk patients and at regular intervals in all adults from the age of 20 years. A scoring system should be used to calculate ASCVD risk that includes known lipid and non-lipid risk factors. Primary treatment targets include low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Lifestyle modifications should be first-line treatment for all patients; the first-line pharmacological treatment targeting plasma lipids in patients at moderate-to-high risk of ASCVD is statin therapy, with a number of adjunctive or second-line agents available. Guidance is also provided on the management of underlying conditions and special populations; of particular pertinence in the region are familial hypercholesterolaemia, diabetes and metabolic dyslipidaemia. Conclusions These consensus clinical recommendations provide practicing clinicians with comprehensive, region-specific guidance to improve the detection and management of plasma lipid disorders in patients in the Middle East.",
keywords = "Cardiovascular disease, Dyslipidaemia, Guidelines, Lipid disorder, Middle East",
author = "{Al Sayed}, Nasreen and {Al Waili}, Khalid and Fatheya Alawadi and Saeed Al-Ghamdi and {Al Mahmeed}, Wael and Fahad Al-Nouri and {Al Rukhaimi}, Mona and Khalid Al-Rasadi and Zuhier Awan and Mohamed Farghaly and Mohamed Hassanein and Hani Sabbour and Mohammad Zubaid and Philip Barter",
year = "2016",
month = "12",
day = "15",
doi = "10.1016/j.ijcard.2016.09.081",
language = "English",
volume = "225",
pages = "268--283",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East

AU - Al Sayed, Nasreen

AU - Al Waili, Khalid

AU - Alawadi, Fatheya

AU - Al-Ghamdi, Saeed

AU - Al Mahmeed, Wael

AU - Al-Nouri, Fahad

AU - Al Rukhaimi, Mona

AU - Al-Rasadi, Khalid

AU - Awan, Zuhier

AU - Farghaly, Mohamed

AU - Hassanein, Mohamed

AU - Sabbour, Hani

AU - Zubaid, Mohammad

AU - Barter, Philip

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Background Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease (ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-specific guidelines for managing plasma lipids exist and there is a lack of use of guidelines developed in other regions. Methods A multidisciplinary panel of regional experts was convened to develop consensus clinical recommendations for the management of plasma lipids in the Middle East. The panel considered existing international guidelines and regional clinical experience to develop recommendations. Results The panel's recommendations include plasma lipid screening, ASCVD risk calculation and treatment considerations. The panel recommend that plasma lipid levels should be measured in all at-risk patients and at regular intervals in all adults from the age of 20 years. A scoring system should be used to calculate ASCVD risk that includes known lipid and non-lipid risk factors. Primary treatment targets include low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Lifestyle modifications should be first-line treatment for all patients; the first-line pharmacological treatment targeting plasma lipids in patients at moderate-to-high risk of ASCVD is statin therapy, with a number of adjunctive or second-line agents available. Guidance is also provided on the management of underlying conditions and special populations; of particular pertinence in the region are familial hypercholesterolaemia, diabetes and metabolic dyslipidaemia. Conclusions These consensus clinical recommendations provide practicing clinicians with comprehensive, region-specific guidance to improve the detection and management of plasma lipid disorders in patients in the Middle East.

AB - Background Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease (ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-specific guidelines for managing plasma lipids exist and there is a lack of use of guidelines developed in other regions. Methods A multidisciplinary panel of regional experts was convened to develop consensus clinical recommendations for the management of plasma lipids in the Middle East. The panel considered existing international guidelines and regional clinical experience to develop recommendations. Results The panel's recommendations include plasma lipid screening, ASCVD risk calculation and treatment considerations. The panel recommend that plasma lipid levels should be measured in all at-risk patients and at regular intervals in all adults from the age of 20 years. A scoring system should be used to calculate ASCVD risk that includes known lipid and non-lipid risk factors. Primary treatment targets include low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Lifestyle modifications should be first-line treatment for all patients; the first-line pharmacological treatment targeting plasma lipids in patients at moderate-to-high risk of ASCVD is statin therapy, with a number of adjunctive or second-line agents available. Guidance is also provided on the management of underlying conditions and special populations; of particular pertinence in the region are familial hypercholesterolaemia, diabetes and metabolic dyslipidaemia. Conclusions These consensus clinical recommendations provide practicing clinicians with comprehensive, region-specific guidance to improve the detection and management of plasma lipid disorders in patients in the Middle East.

KW - Cardiovascular disease

KW - Dyslipidaemia

KW - Guidelines

KW - Lipid disorder

KW - Middle East

UR - http://www.scopus.com/inward/record.url?scp=84991489156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991489156&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.09.081

DO - 10.1016/j.ijcard.2016.09.081

M3 - Review article

C2 - 27741487

AN - SCOPUS:84991489156

VL - 225

SP - 268

EP - 283

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -